Cargando…

Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients

Detalles Bibliográficos
Autores principales:	Palich, R., Veyri, M., Marot, S., Vozy, A., Gligorov, J., Maingon, P., Marcelin, A.-G., Spano, J.-P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society for Medical Oncology. Published by Elsevier Ltd. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081573/ https://www.ncbi.nlm.nih.gov/pubmed/33932501 http://dx.doi.org/10.1016/j.annonc.2021.04.020

Ejemplares similares

High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers
por: Palich, R., et al.
Publicado: (2021)

Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma
por: Poizot-Martin, Isabelle, et al.
Publicado: (2022)

Determining the Optimal SARS-CoV-2 mRNA Vaccine Dosing Interval for Maximum Immunogenicity
por: Asamoah-Boaheng, Michael, et al.
Publicado: (2023)

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
por: Malard, Florent, et al.
Publicado: (2021)

Interpretation of SARS-CoV-2 replication according to RT-PCR crossing threshold value
por: Marot, Stéphane, et al.
Publicado: (2021)

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis
por: Anderson, Evan, et al.
Publicado: (2022)

Su1489: HUMORAL IMMUNOGENICITY OF THREE SARS-COV-2 MRNA VACCINE DOSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Schell, Trevor, et al.
Publicado: (2022)

High SARS-CoV-2 seroprevalence in HIV patients originating from sub-Saharan Africa in the Ile-de-France area: Seroprevalence of SARS-CoV-2 in HIV patients
por: ABDI, Basma, et al.
Publicado: (2022)

Epidemiology and Characteristics of SARS-CoV-2 Variants of Concern: The Impacts of the Spike Mutations
por: Cocherie, Théophile, et al.
Publicado: (2022)

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
por: Anderson, Evan J., et al.
Publicado: (2020)

Increase in SARS-CoV-2 Seroprevalence in UK Domestic Felids Despite Weak Immunogenicity of Post-Omicron Variants
por: Tyson, Grace B., et al.
Publicado: (2023)

112P Immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in cancer patients receiving immunotherapy agents
por: Muñoz, F. Longo, et al.
Publicado: (2021)

Immunogenicity of Sars-Cov-2 mRNA 1273 Vaccine in Patients with Lymphoid Malignancies
por: Dong, Ning, et al.
Publicado: (2021)

Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine
por: Zeng, Guangting
Publicado: (2022)

Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination
por: König, Marton, et al.
Publicado: (2022)

Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients
por: Chevallier, Patrice, et al.
Publicado: (2021)

Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept
por: Chavarot, Nathalie, et al.
Publicado: (2021)

SARS-CoV-2 variant-dependent inflammasome activation
por: Teyssou, Elisa, et al.
Publicado: (2023)

Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
por: Gougis, Paul, et al.
Publicado: (2020)

Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2 Infection
por: Petonnet, Dorian, et al.
Publicado: (2022)

Immunogenicity of SARS‐CoV‐2 mRNA vaccine in solid organ transplant recipients
por: Holden, Inge K., et al.
Publicado: (2021)

Immunogenicity of SARS-CoV-2 mRNA intramuscular vaccination in patients with muscular disorders
por: Kasai, Ryousuke, et al.
Publicado: (2023)

Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2
por: Deepak, Parakkal, et al.
Publicado: (2021)

Evaluation of Immunogenicity to Three Doses of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Lung Transplant Patients
por: Guardiani, Mariasilvia, et al.
Publicado: (2022)

Immunogenicity of Multiple Doses of pDNA Vaccines against SARS-CoV-2
por: Almansour, Iman, et al.
Publicado: (2021)

Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis
por: Strengert, Monika, et al.
Publicado: (2021)

Baseline Gut Microbiome Signatures Correlate with Immunogenicity of SARS-CoV-2 mRNA Vaccines
por: Daddi, Lauren, et al.
Publicado: (2023)

Kaposi’s Sarcoma in Virally Suppressed People Living with HIV: An Emerging Condition
por: Palich, Romain, et al.
Publicado: (2021)

Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination
por: Jongkees, Marlou J, et al.
Publicado: (2022)

Immunogenicity of three doses of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologics
por: Graceffa, Dario, et al.
Publicado: (2022)

Long-term evolution of humoral immune response after SARS-CoV-2 infection
por: Teyssou, Elisa, et al.
Publicado: (2022)

Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients
por: Haller, Maria C., et al.
Publicado: (2022)

Humoral and Cellular Responses to a Delayed Fourth SARS-CoV-2 mRNA-Based Vaccine in Weak Responders to 3 Doses Kidney Transplant Recipients
por: Del Bello, Arnaud, et al.
Publicado: (2022)

The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients
por: Zitt, Emanuel, et al.
Publicado: (2021)

Kaposi’s Sarcoma-Associated Herpesvirus, the Etiological Agent of All Epidemiological Forms of Kaposi’s Sarcoma
por: Jary, Aude, et al.
Publicado: (2021)

Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine
por: Takano, Tomohiro, et al.
Publicado: (2022)

Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
por: Jiménez, Moraima, et al.
Publicado: (2022)

Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2
por: Salleh, Mohd Zulkifli, et al.
Publicado: (2022)

Immunogenicity and Safety of mRNA Anti-SARS-CoV-2 Vaccines in Patients with Systemic Lupus Erythematosus
por: Mormile, Ilaria, et al.
Publicado: (2022)

Immunogenicity of the Two mRNA SARS-CoV-2 Vaccines in a Large Cohort of Dialysis Patients
por: Tsoutsoura, Paraskevi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3kskl9ioi8995urc5q98c9jve9